Physician profile
Paul Choinski
NPI 1174599062
$5,684.01
in general payments reported to CMS, 2019-2025
30 companies · $622 in 2025
The $622 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $901 · 2020: $390 · 2021: $357 · 2022: $1,243 · 2023: $1,146 · 2024: $1,025 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,775 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,775.44 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,508.84 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Alcon Vision LLC | $606.90 | 2019-2025 | Simbrinza, Clareon |
| Allergan, INC. | $601.32 | 2019-2022 | |
| Ocular Therapeutix, INC. | $347.17 | 2022-2025 | Dextenza |
| Oyster Point Pharma, INC. | $298.81 | 2022-2025 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $263.40 | 2019-2021 | |
| Glaukos Corporation | $263.19 | 2019-2024 | Idose, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Sun Pharmaceutical Industries INC. | $224.23 | 2020-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $221.26 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $186.17 | 2021-2022 | |
| Rxsight INC | $161.96 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Tarsus Pharmaceuticals, INC. | $133.42 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $121.62 | 2022-2025 | Miebo, Envista Mx60 Iol, Prolensa |
| Eyevance Pharmaceuticals LLC | $108.90 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $78.55 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $65.18 | 2024-2025 | Vevye |
| Revance Therapeutics, INC. | $61.95 | 2025 | Daxxify |
| Apellis Pharmaceuticals, INC. | $55.50 | 2025 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $49.41 | 2019-2020 | |
| Shire North American Group INC | $47.67 | 2019 | |
| Sight Sciences, INC. | $43.57 | 2022-2023 | Omni Surgical System |
| Amgen INC. | $42.56 | 2025 | Tepezza |
| Dompe US, INC. | $33.67 | 2022 | |
| Astellas Pharma US INC | $31.57 | 2024 | Izervay |
| Merck Sharp & Dohme LLC | $30.79 | 2023-2024 | Bridion |
| Biotissue Holdings INC. | $24.96 | 2024 | |
| New World Medical,INC. | $21.57 | 2024 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Mallinckrodt Enterprises LLC | $18.99 | 2019 | |
| Omeros Corporation | $16.49 | 2020 | |
| Santen INC. | $14.39 | 2023 | Verkazia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Choinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.